WX [WuXi PharmaTech (Cayman)] S-8 POS: (Original Filing)
[]
CPHI [CHINA PHARMA] 8-K: (Original Filing)
[--------------- FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): December 8, 2015 CHINA PHARMA HOLDINGS, INC. --------------------------------------- Nevada 001-34471 73-1564807 (State or other jurisdiction (Commission File No.) (IRS Employer of Incorporation) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) Item 5.07 Submission of Matters to a Vote of]
CPHI [CHINA PHARMA] 8-K: ————— FORM 8-K CURRENT REPORT Date of Report
[--------------- FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): December 8, 2015 CHINA PHARMA HOLDINGS, INC. --------------------------------------- Nevada 001-34471 73-1564807 (State or other jurisdiction (Commission File No.) (IRS Employer of Incorporation) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) Item 5.07 Submission of Matters to a Vote of]
TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)
[TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements Tianyin Pharmaceutical Inc. (NYSE Amex: TPI) (the “Company”), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), received notice on November 25, 2015 from the NYSE MKT LLC (the “Exchange”) indicating that the Company is below certain] []
TPI [TIANYIN PHARMACEUTICAL] 8-K: TPI Received Notice of Non-Compliance with NYSE MKT
[TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements Tianyin Pharmaceutical Inc. (NYSE Amex: TPI) (the “Company”), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), received notice on November 25, 2015 from the NYSE MKT LLC (the “Exchange”) indicating that the Company is below certain] []
WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[Form 6-K TABLE OF CONTENTS 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
BSPM [Biostar Pharmaceuticals] 10-Q: (Original Filing)
[FORM 10-Q (Mark One) x September 30, 2015 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Ronghua Wang EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Qinghua Liu Qinghua Liu Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]
BSPM [Biostar Pharmaceuticals] 10-Q: FORM 10-Q (Mark One) x September 30, 2015
[FORM 10-Q (Mark One) x September 30, 2015 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Ronghua Wang EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Qinghua Liu Qinghua Liu Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]
WX [WuXi PharmaTech (Cayman)] SC 13E3/A: EXECUTION VERSION U.S.$800,000,000 FACILITY AGREEMENT dated November 20,
[EXECUTION VERSION U.S.$800,000,000 FACILITY AGREEMENT dated November 20, 2015 for WUXI MERGER LIMITED arranged by PING AN BANK CO., LTD. ( DEVELOPMENT BANK CO., LTD. ( as Mandated Lead Arrangers with SHANGHAI PUDONG DEVELOPMENT BANK CO., LTD. ( as Facility Agent and PING AN BANK CO., LTD. ( as Security Agent CONTENTS CLAUSE PAGE SECTION 1 INTERPRETATION 1 1. Definitions] [EXECUTION VERSION U.S.$300,000,000 FACILITY AGREEMENT November 20, dated for GROUP & CLOUD LIMITED arranged by PING AN BANK CO., LTD. ( DEVELOPMENT BANK CO., LTD. ( as Mandated Lead Arrangers with SHANGHAI PUDONG DEVELOPMENT BANK CO., LTD. ( as Facility Agent and PING AN BANK CO., LTD. ( as Security Agent CONTENTS CLAUSE PAGE SECTION 1 INTERPRETATION 1 1. Definitions] [SECOND AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER Amendment Parent Merger Sub Company This SECOND AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER, dated as of November 20, 2015 (this Agreement WHEREAS, Parent, Merger Sub and the Company desire to enter into this Amendment, which shall amend the Agreement in accordance with the terms and conditions set forth] []
